Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381394 | 0.88 | TP53 (0.48) | NAMPTTDP1ROCK2MAPT | |
| SCHEMBL1381498 | 0.88 | KCNJ1 (0.55) | NAMPTTDP1 | |
| SCHEMBL4499599 | 0.88 | NAMPT (0.53) | NAMPTTDP1 | |
| SCHEMBL1377890 | 0.85 | NAMPT (0.53) | NAMPTTDP1MAPT | |
| SCHEMBL4494287 | 0.85 | ROCK2 (0.50) | NAMPTTDP1ROCK2 | |
| SCHEMBL1379465 | 0.85 | LMNA (0.53) | TDP1ROCK2 | |
| SCHEMBL4490447 | 0.85 | NAMPT (0.53) | NAMPTTDP1MAPT | |
| SCHEMBL1378774 | 0.83 | ROCK2 (0.53) | NAMPTTDP1ROCK2 | |
| SCHEMBL4497230 | 0.82 | HTT (0.55) | TDP1ROCK2 | |
| SCHEMBL14065323 | 0.82 | TP53 (0.49) | NAMPTTDP1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4769720-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | claimed |
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | NAMPT 588/4885TDP1 3696/4885PKM 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.